Abzena

Join us tomorrow from 11:30-12:30 pm EST for a live webinar, "Mastering the Art of Developing a Successful Bispecific Antibody." Abzena’s Senior Scientist, Dr. Timothy Wood, will present key insights into the design and development of bispecific antibodies, covering crucial topics such as avidity, spacing, and formatting strategies leading to successful outcomes. Don’t miss the chance to gain valuable insights into strategies and methodologies for optimizing bispecific antibody candidates for development and manufacture. Register now to discover how Abzena can help support your bispecific antibody program: https://lnkd.in/ehysRCs9 #BispecificAntibodies #Biologics #DrugDevelopment #CDMO #AntibodyEngineering #Webinar #CRO

At #ChemOutsourcing this week, Abzena’s CTO, Dr. Louise Duffy, participated in a panel discussion focused on oncology drug development and the role of ADC/PDC CDMO partnerships. With key insights shared about ADC/PDC drug development and the challenges posed by managing supply chain complexities in contract manufacturing.   Abzena’s extensive ADC services, spanning from early discovery and development through GMP manufacturing, were emphasized as a significant differentiator in advancing these complex therapeutics. Our integrated approach ensures efficient, scalable solutions to support this advancement of next generation therapies.   Learn more about how our ADC services can advance your program seamlessly from concept to commercialization: https://lnkd.in/gk9YDcTA   #ADCs #DrugDevelopment #CDMO #GMP #Biologics #ADCCDMO #CRO

Formulation development is an essential part of the biopharmaceutical drug development process. This critical step can make or break a biologic's clinical and commercial success. In a recent article in Manufacturing Chemist, Gary Watts, Senior Manager and Head of Formulation, discusses the pivotal role that formulation development plays and key strategies that aid in transforming promising biopharmaceutical compounds into effective therapies.   Gary states, "Formulation development is more than just creating a drug that works, it helps to ensure that the drug reaches those who need it most in a form that maximizes its therapeutic potential."   At Abzena, we take a proactive approach to formulation development that involves conducting stress tests at the preliminary stages, which helps to identify issues before they escalate into major obstacles. This unique approach allows us to streamline and de-risk the development path to the clinic for our customer's promising therapies.   Access the article to learn more: https://lnkd.in/ebgVWKys   #FormulationDevelopment #Biologics #DrugDevelopment #CDMO #CRO #Biotechnology #Pharmaceuticals

Join us at the upcoming Sept. 10th PBSS Workshop on "Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities." Our drug development experts, Sudha Krishnan and Zoe Yi Zhang, will be on hand to discuss how our fully integrated services can de-risk your antibody's or ADC's development path to IND and beyond.   From ADC and linker-payload design to developability and GMP manufacture, schedule a meeting with them at the event to learn how Abzena’s tailored solutions can streamline your bioconjugate's progression from discovery through to commercial launch.   Click here to schedule a meeting: https://lnkd.in/gTQG6j26   #Biologics #ADCCDMO #DrugDevelopment #CRO #CDMO #IND #BLA

Designing and generating #antibodies can be a complex and challenging process. At Abzena, we offer comprehensive antibody discovery and engineering services that streamline and de-risk this critical phase, moving biologics from concept to candidate selection with precision and expertise. Leveraging expert assessments of target molecules, immunization strategies and antibody screening cascades, we generate robust data that ensures optimal antibody discovery and supports the selection of the best antibody candidate for your drug development program. Our discovery methods are focused on ensuring high affinity antibodies and include flow cytometry, SPR analysis, in vitro assays, epitope binning and hybridoma sequencing. Learn more about how our comprehensive suite of discovery services can streamline your antibody program from concept to lead candidate selection today: https://lnkd.in/e8QMNi2P #Biologics #DrugDiscovery #CRO #CDMO #drugdevelopment

Labor Day is a time to recognize and appreciate the dedication and hard work of our teams and our partners that keep our business moving forward. At Abzena, we're fortunate to have a team, whose expertise and commitment are at the core of every biopharmaceutical program that we help develop. Focused on collaboration and precision, our experts are the driving force behind some of the most innovative technologies and therapeutic advancements. Your efforts ensure that we continue to make strides in transforming our customer's complex challenges into life-saving treatments for patients in need.   Thank you for your continued dedication and the vital role you play in our shared mission to move medicines forward faster.   #LaborDay #EmployeeAppreciation #BiologicsDevelopment #Innovation #HealthcareAdvancements

Process development is essential for ensuring a consistent, scalable and high-quality production of biologic drugs, from early development to commercialization. At Abzena, both upstream and downstream process development are crucial parts of our service offering where we focus on refining and optimizing processes to accelerate timelines and ensure scalability. In our latest blog, Jennifer Hopp, Sr. Director of Process Development, discusses how our platform processes, advanced technologies, and collaborative approach streamline #antibody development. Learn more about how our process development services can best support your biologic program. Access the full blog here: https://lnkd.in/eAd3qC2F #Biologics #ProcessDevelopment #DrugDevelopment #CRO #CDMO #Manufacturing

Understanding potential developability challenges earlier in the process can determine whether a biologic or bioconjugate will successfully move from discovery to market. At Abzena, we de-risk the drug development process as early as possible to ensure that your therapeutic candidates are manufacturable, safe, and efficacious.   Our approach combines decades of experience with advanced methodologies and bioassays to evaluate everything from design and optimization to immunogenicity and manufacturability. By addressing key questions—Can we make it? Does it work?—we identify and mitigate potential risks, streamlining the development process.   Explore our latest info sheet to learn how our unique approach to developability can help advance your biologic or bioconjugate forward with greater success.    Click here to learn more: https://lnkd.in/gktKNFXK #Biologics #Bioconjugates #DrugDevelopment #CRO #CDMO #Developability 

At Abzena, our scientists are experts in addressing the complexities in Antibody-drug Conjugate (#ADC) design, development, and manufacture. We always strive to deliver results that exceed our partners’ expectations and our collaboration with DYJ Pharma Consulting reflects that commitment to quality and seamless project execution. David Jackson, Pharmaceutical Consultant & ADC Expert at DYJ Pharma Consulting, shared his experience: “I’ve never had a CRO project go this smoothly and the ADCs delivered were very high quality. I’m confident that my client will put Abzena at the top of their list for future ADC projects.” Hear what our other partners have shared and discover how we can assist in rapidly advancing your ADC projects today: https://lnkd.in/e8dw4FRM #CustomerSuccess #CRO #CDMO #ADCs #DrugDevelopment #ADCCDMO

In a collaborative journal article with Regeneron, Abzena’s scientific team explores the development of potent rifampicin derivatives to combat drug-resistant bacterial strains. This research highlights how innovative chemistry and a strategic approach can lead to new solutions in the fight against antimicrobial resistance. The article underscores the significance of tailored antibiotic development strategies, focusing on enhancing the activity of rifampicin derivatives to address the growing challenge of drug resistance. Read the full article here: https://lnkd.in/eqig585w #Antibiotics #DrugDevelopment #Pharmaceuticals #AntimicrobialResistance #CDMO #CRO